Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port |
| |
| Affiliation: | 1. Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany;2. Institute of Pathophysiology, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands;2. Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands;3. Department of Cardiology, Treant Zorggroep, Location Scheper, Emmen, the Netherlands;4. Department of Cardiology, Ziekenhuisgroep Twente, Almelo and Hengelo, the Netherlands;5. Health Technology and Services Research, MIRA—Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the Netherlands;1. Cardiology Department, St. Thomas'' Hospital, Guys and St Thomas'' NHS Foundation Trust, London, UK;2. Cardiology Department, Essex Cardiothoracic Centre, Basildon & Thurrock University Hospitals Foundation NHS Trust, Basildon, UK |
| |
| Abstract: | 170 patients were treated with continuous infusion of epirubicin, mitoxantrone, carboplatin or 5-fluorouracil through an implanted venous access port with a portable infusion pump. A total of 440 cycles were given on an outpatient basis. The patients were instructed how to dissolve their drugs and to change the syringes. The complication rate was low. 10 patients developed a thrombosis of the subclavian vein, resulting in cessation of therapy in 5. Pulmonary embolism occurred twice, in 1 patient during a period of subclavian vein thrombosis. Needle dislocation occurred 6 times and catheter occlusion 20 times. Patency was restored with saline or urokinase. Local infection occurred 3 times and systemic infection only once. This technique is suitable for continuous infusion of different cytostatic drugs on an outpatient basis. Patients were able to prepare their drugs at home and the system can remain in situ for 3 weeks without increasing the complication rate. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
